CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New CIDP treatment seeks to match established therapy
Disease control Recruiting nowThis study aims to see if a new immunoglobulin treatment called TAK-881 works similarly in the body to an existing treatment called HYQVIA for adults with CIDP. Participants who are already receiving immunoglobulin therapy will switch between the two treatments over several month…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New treatment tested for rare nerve disease that causes weakness
Disease control Recruiting nowThis study is testing whether a modified form of immunoglobulin called TAK-411 can improve physical function and reduce symptoms in adults with CIDP, a rare autoimmune disease that damages nerves and causes muscle weakness. About 36 participants who have previously responded to s…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Tracking the switch: do patients prefer this new CIDP treatment?
Knowledge-focused Recruiting nowThis study aims to understand why adults with a nerve disorder called CIDP switch to a treatment called HyQvia and how it affects their daily lives. Researchers will follow about 30 people for a year, collecting information through medical records and questionnaires about their s…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Mar 18, 2026 18:25 UTC